John Lambert
PhD
Former Vice President, ADC Research
👥Biography 个人简介
John Lambert is a founding figure in the antibody-drug conjugate field who developed maytansinoid payloads (DM1, DM4) that enabled ado-trastuzumab emtansine (T-DM1), the first approved ADC for solid tumors. His decades of work on conjugation chemistry and payload optimization established the scientific foundations for the modern ADC industry. His contributions have influenced virtually every subsequent ADC program.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 John Lambert 的研究动态
Follow John Lambert's research updates
留下邮箱，当我们发布与 John Lambert（ImmunoGen (Founder/Pioneer)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment